LONDON, March 13 /PRNewswire-FirstCall/ -- Silence Therapeutics plc (AIM: SLN) today announces a collaboration with AstraZeneca (LSE: AZN), focused on the development of a range of novel approaches for the delivery of siRNA molecules. The deal builds on Silence Therapeutics' leading expertise in the delivery of siRNA molecules, in particular its success with the functional systemic delivery of siRNA in vivo using its proprietary AtuPLEX technology. The financial details of this collaboration, in which both parties will contribute expertise and know-how, have not been disclosed.
This new deal is independent of the parties' three-year collaboration signed in July 2007, whose aim is to develop novel siRNA therapeutics against specific targets exclusive to AstraZeneca.
As a result of today's agreement, Silence Therapeutics and AstraZeneca will work together to develop new and improved approaches for the delivery of siRNA molecules. The successful delivery of siRNA molecules to different tissue sites is critical to realize the exciting potential of siRNA to treat a broad range of diseases. Under the terms of the agreement both Silence Therapeutics and AstraZeneca will be allowed to commercialise the truly novel delivery systems that they develop together.
Jeff Vick, CEO of Silence Therapeutics, commenting on today's announcement said, "We are delighted to enter this new collaboration with AstraZeneca for the development of novel approaches for the delivery of siRNA molecules. This agreement highlights the significant progress we have made with our AtuPLEX platform, following our early realization of the importance of delivery to the development of successful RNAi therapeutics. This deal also reflects the strong working relationship we have developed with AstraZeneca and the progress of our ongoing collaboration in the development of AtuRNAi molecules against a number of their targets."
Mr. Vick continued, "We look forward to continuing
|SOURCE Silence Therapeutics plc|
Copyright©2008 PR Newswire.
All rights reserved